Crystallographic analysis reveals that anticancer clinical candidate L-778,123 inhibits protein farnesyltransferase and geranylgeranyltransferase-I by different binding modes.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples